Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunovant, Inc.

15.80
-0.0600-0.38%
Post-market: 15.800.00000.00%17:04 EDT
Volume:1.91M
Turnover:30.09M
Market Cap:2.70B
PE:-5.79
High:16.04
Open:16.04
Low:15.44
Close:15.86
Loading ...

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data

Benzinga
·
20 Mar

Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright

TIPRANKS
·
20 Mar

Immunovant Shares Down 5.2% After Late-Stage Data for Its Experimental Muscle Disorder Drug

THOMSON REUTERS
·
19 Mar

Roivant says Immunovant announces results from Phase 3 study of batoclimab in MG

TIPRANKS
·
19 Mar

Immunovant's muscle disorder treatment meets main goal in late-stage trial

Reuters
·
19 Mar

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (Mg) and Chronic Inflammatory Demyelinating Polyneuropathy (Cidp) Studies

THOMSON REUTERS
·
19 Mar

Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity

Blockhead
·
05 Mar

Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (AKRO), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
03 Mar

Jefferies Initiates Immunovant at Hold With $20 Price Target

MT Newswires Live
·
03 Mar

Immunovant initiated with a Hold at Jefferies

TIPRANKS
·
03 Mar

Immunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to Analysts

Insider Monkey
·
24 Feb

Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now?

Insider Monkey
·
22 Feb

Stifel Nicolaus Remains a Buy on Immunovant (IMVT)

TIPRANKS
·
21 Feb

Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently

Insider Monkey
·
20 Feb

Analysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
11 Feb

Q3 2024 Roivant Sciences Ltd Earnings Call

Thomson Reuters StreetEvents
·
11 Feb

Stock Track | Immunovant, Inc. Plummets 5.10% on Wider-Than-Expected Quarterly Loss

Stock Track
·
11 Feb

Immunovant Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
10 Feb

Immunovant Is Maintained at Buy by Guggenheim

Dow Jones
·
10 Feb

J.P. Morgan Keeps Their Buy Rating on Immunovant (IMVT)

TIPRANKS
·
08 Feb